semaglutide dopamine GLP-1 was approved as a weight loss drug. Nobody told you it might also be killing your addictions. Friends and people I know on GLP-1s have been reporting an entire stream of Neurobiological Mechanisms and Therapeutic Potential

DT received lecture or consultancy fees from Amarin, AstraZeneca, Eli Lilly, and Novo Nordisk

Emerging Research Directions Beyond the standard protocols, researchers are exploring several innovative applications: Combination with newer agents Investigating cagrilintide paired with emerging compounds like retatrutide or other multi-receptor agonists

Use of WEGOVY for this indication is supported by a 68-week, double-blind, placebo-controlled clinical trial in 201 pediatric patients aged 12 years and older with a BMI corresponding to 95th percentile for age and sex and from studies in adult patients with obesity [see Clinical Studies (14.3)]

Eine Ausnahme bildet Tirzepatid: Der Wirkstoff ahmt nicht nur GLP-1, sondern auch GIP nach, ein weiteres Darmhormon

Although both medications can support weight reduction, their differences may make one more suitable than the other depending on the individual and their health needs